{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:36:43Z","timestamp":1794101803977,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03303-7","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:59:13Z","timestamp":1753261153000},"page":"4583-4596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Prophylaxis Outcomes with rIX-FP and rFIXFc for Males with Hemophilia B: Pooled Analysis of Medical Chart Data from Germany and Italy"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1585-4100","authenticated-orcid":false,"given":"Johannes","family":"Oldenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-6244","authenticated-orcid":false,"given":"Martin","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-3839","authenticated-orcid":false,"given":"Songkai","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7079-5927","authenticated-orcid":false,"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radovan","family":"Tomic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7388-2013","authenticated-orcid":false,"given":"Douglass","family":"Drelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Jakobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8934-2936","authenticated-orcid":false,"given":"Mariasanta","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"Suppl 6","key":"3303_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH Guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"8","key":"3303_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","volume":"11","author":"G Castaman","year":"2018","unstructured":"Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol. 2018;11(8):673\u201383.","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"3303_CR3","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","volume":"120","author":"E Santagostino","year":"2012","unstructured":"Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120(12):2405\u201311.","journal-title":"Blood"},{"issue":"4","key":"3303_CR4","first-page":"634","volume":"102","author":"HJ Metzner","year":"2009","unstructured":"Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost. 2009;102(4):634\u201344.","journal-title":"Thromb Haemost"},{"issue":"24","key":"3303_CR5","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","volume":"369","author":"JS Powell","year":"2013","unstructured":"Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313\u201323.","journal-title":"N Engl J Med"},{"issue":"14","key":"3303_CR6","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","volume":"127","author":"E Santagostino","year":"2016","unstructured":"Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761\u20139.","journal-title":"Blood"},{"issue":"1","key":"3303_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/03007995.2019.1662675","volume":"36","author":"J Oldenburg","year":"2020","unstructured":"Oldenburg J, Yan S, Maro G, Krishnarajah G, Tiede A. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy. Curr Med Res Opin. 2020;36(1):9\u201315.","journal-title":"Curr Med Res Opin"},{"key":"3303_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/ejh.14168","volume":"112","author":"P Giordano","year":"2024","unstructured":"Giordano P, Pollio B, Sottilotta G, Biasoli C, Daniele F, De Cristofaro R, et al. Pattern of use and clinical outcomes with rIX-FP in pediatric\/adolescent patients with haemophilia B in Italy: results from IDEAL real-world study. Eur J Haematol. 2024;112:765\u201375.","journal-title":"Eur J Haematol"},{"issue":"1","key":"3303_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/hae.14689","volume":"29","author":"A Tagliaferri","year":"2023","unstructured":"Tagliaferri A, Molinari AC, Peyvandi F, Coppola A, Demartis F, Biasoli C, et al. IDEAL study: a real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy. Haemophilia. 2023;29(1):135\u201344.","journal-title":"Haemophilia"},{"issue":"6","key":"3303_CR10","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1007\/s12325-020-01300-6","volume":"37","author":"C Hermans","year":"2020","unstructured":"Hermans C, Marino R, Lambert C, Mangles S, Sommerer P, Rives V, et al. Real-world utilisation and bleed rates in patients with Haemophilia B who switched to recombinant factor ix fusion protein (rIX-FP): a retrospective international analysis. Adv Ther. 2020;37(6):2988\u201398.","journal-title":"Adv Ther"},{"issue":"5","key":"3303_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102482","volume":"8","author":"C Bidlingmaier","year":"2024","unstructured":"Bidlingmaier C, Heller C, Langer F, Miesbach W, Scholz U, Oldenburg J, et al. Real-world usage and effectiveness of recombinant factor VIII\/factor IX Fc in hemophilia A\/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany. Res Pract Thromb Haemost. 2024;8(5): 102482.","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"3303_CR12","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3390\/jcm13051518","volume":"13","author":"A Coppola","year":"2024","unstructured":"Coppola A, Rivolta GF, Quintavalle G, Matichecchia A, Riccardi F, Rossi R, et al. Six-year, real-world use of prophylaxis with recombinant factor IX-albumin fusion protein (rIX-FP) in persons with hemophilia B: a single-center retrospective-prospective study. J Clin Med. 2024;13(5):1518.","journal-title":"J Clin Med"},{"key":"3303_CR13","unstructured":"IDELVION (albutrepenonacog alfa) Summary of Product Characteristics. West Sussex, UK: CSL Behring; 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/idelvion-epar-product-information_en.pdf. Accessed date 14 Feb 2024."},{"issue":"5","key":"3303_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1055\/s-0036-1571315","volume":"42","author":"E Berntorp","year":"2016","unstructured":"Berntorp E, Andersson NG. Prophylaxis for hemophilia in the era of extended half-life factor VIII\/factor IX products. Semin Thromb Hemost. 2016;42(5):518\u201325.","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"3303_CR15","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/jth.14778","volume":"18","author":"ME Mancuso","year":"2020","unstructured":"Mancuso ME, Lubetsky A, Pan-Petesch B, Lissitchkov T, Nagao A, Seifert W, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults\/adolescents with hemophilia B. J Thromb Haemost. 2020;18(5):1065\u201374.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"3303_CR16","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1111\/hae.14036","volume":"26","author":"KJ Pasi","year":"2020","unstructured":"Pasi KJ, Fischer K, Ragni M, Kulkarni R, Ozelo MC, Mahlangu J, et al. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: results from the B-YOND extension study. Haemophilia. 2020;26(6):e262\u201371.","journal-title":"Haemophilia"},{"issue":"4","key":"3303_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1055\/s-0040-1705116","volume":"120","author":"G Kenet","year":"2020","unstructured":"Kenet G, Chambost H, Male C, Halimeh S, Lambert T, Li Y, et al. Long-term safety and efficacy of recombinant coagulation factor IX albumin fusion protein (rIX-FP) in previously treated pediatric patients with hemophilia B: results from a Phase 3b extension study. Thromb Haemost. 2020;120(4):599\u2013606.","journal-title":"Thromb Haemost"},{"issue":"4","key":"3303_CR18","first-page":"659","volume":"116","author":"G Kenet","year":"2016","unstructured":"Kenet G, Chambost H, Male C, Lambert T, Halimeh S, Chernova T, et al. Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. Thromb Haemost. 2016;116(4):659\u201368.","journal-title":"Thromb Haemost"},{"issue":"7","key":"3303_CR19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/03007995.2022.2062180","volume":"38","author":"M Olivieri","year":"2022","unstructured":"Olivieri M, Simpson M, Yan S, Fedorovsky J, Zhang X, Tomic R, et al. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A. Curr Med Res Opin. 2022;38(7):1133\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"3303_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/ejh.13378","volume":"104","author":"M Olivieri","year":"2020","unstructured":"Olivieri M, Sommerer P, Maro G, Yan S. Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII-SingleChain and other common rFVIII products in Germany. Eur J Haematol. 2020;104(4):310\u20137.","journal-title":"Eur J Haematol"},{"issue":"4","key":"3303_CR21","first-page":"504","volume":"26","author":"M Simpson","year":"2020","unstructured":"Simpson M, Desai V, Maro G, Yan S. Comparing factor use and bleed rates in US hemophilia a patients receiving prophylaxis with 3 different long-acting recombinant factor VIII products. J Manag Care Spec Pharm. 2020;26(4):504\u201312.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"3303_CR22","first-page":"1258","volume":"26","author":"S Yan","year":"2020","unstructured":"Yan S, Maro G, Desai V, Simpson M. A real-world analysis of commonly prescribed FVIII products based on US medical charts: consumption and bleeding outcomes in hemophilia A patients. J Manag Care Spec Pharm. 2020;26(10):1258\u201365.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"3303_CR23","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/hae.15101","volume":"30","author":"SA Fedewa","year":"2024","unstructured":"Fedewa SA, Cafuir L, Valentino LA, Koo A, Antun A, Kempton CL. Women and girls' participation in haemophilia clinical trials. Haemophilia. 2024;30(6):1440\u20133.","journal-title":"Haemophilia"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03303-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03303-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03303-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:32:37Z","timestamp":1757273557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03303-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3303"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03303-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Johannes Oldenburg has received research funding from Bayer, Biotest, CSL Behring, Octapharma, Pfizer, Swedish Orphan Biovitrum and Takeda; consultancy, speakers bureau, honoraria, scientific advisory board and travel expenses from Bayer, Biogen Idec, BioMarin, Biotest, Chugai, CSL Behring, Freeline, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Spark Therapeutics, Swedish Orphan Biovitrum and Takeda; Martin Olivieri has received grants\/research support from Bayer, Biomarin, Biotest, Takeda, CSL Behring Octapharma, Pfizer, Shire, Roche, Stago and Swedish Orphan Biovitrium, consultancy and speaker fees from Bayer, BioMarin, Biotest, Novo Nordisk, Takeda, CSL Behring, Pfizer, Roche and Swedish Orphan Biovitrium; Songkai Yan, Radovan Tomic, Xiang Zhang and Douglass Drelich are employees of CSL Behring; Ying Yang and Natalie Jakobs are employees of Adivo Associates; Mariasanta Napolitano has acted as consultant for Bayer, Novo Nordisk, Sobi, Kedrion, and has received speaker fees from Takeda, CSL Behring, Bayer, Novo Nordisk, Kedrion, Novartis, Amgen, Sobi, Sanofi Genzyme, Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Following IRB evaluation, the study was determined to be exempt from IRB oversight as it was secondary research using non-identifiable information for which informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical approval"}}]}}